148 related articles for article (PubMed ID: 9857058)
21. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation.
Meyer S; Kohler NG; Joly A
FEBS Lett; 1997 Aug; 413(2):354-8. PubMed ID: 9280312
[TBL] [Abstract][Full Text] [Related]
22. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation.
Dai RM; Li CC
Nat Cell Biol; 2001 Aug; 3(8):740-4. PubMed ID: 11483959
[TBL] [Abstract][Full Text] [Related]
23. The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.
Hunter JE; Butterworth JA; Zhao B; Sellier H; Campbell KJ; Thomas HD; Bacon CM; Cockell SJ; Gewurz BE; Perkins ND
Oncogene; 2016 Jun; 35(26):3476-84. PubMed ID: 26522720
[TBL] [Abstract][Full Text] [Related]
24. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.
Chang YC; Lee YS; Tejima T; Tanaka K; Omura S; Heintz NH; Mitsui Y; Magae J
Cell Growth Differ; 1998 Jan; 9(1):79-84. PubMed ID: 9438391
[TBL] [Abstract][Full Text] [Related]
25. The carboxy-terminus of I kappaB alpha determines susceptibility to degradation by the catalytic core of the proteasome.
Kroll M; Conconi M; Desterro MJ; Marin A; Thomas D; Friguet B; Hay RT; Virelizier JL; Arenzana-Seisdedos F; Rodriguez MS
Oncogene; 1997 Oct; 15(15):1841-50. PubMed ID: 9362451
[TBL] [Abstract][Full Text] [Related]
26. Association between HTLV-1 Tax and I kappa B alpha is dependent on the I kappa B alpha phosphorylation state.
Petropoulos L; Hiscott J
Virology; 1998 Dec; 252(1):189-99. PubMed ID: 9875328
[TBL] [Abstract][Full Text] [Related]
27. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway.
Chen Z; Hagler J; Palombella VJ; Melandri F; Scherer D; Ballard D; Maniatis T
Genes Dev; 1995 Jul; 9(13):1586-97. PubMed ID: 7628694
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells.
Németh ZH; Wong HR; Odoms K; Deitch EA; Szabó C; Vizi ES; Haskó G
Mol Pharmacol; 2004 Feb; 65(2):342-9. PubMed ID: 14742676
[TBL] [Abstract][Full Text] [Related]
29. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.
Schubert U; Antón LC; Bacík I; Cox JH; Bour S; Bennink JR; Orlowski M; Strebel K; Yewdell JW
J Virol; 1998 Mar; 72(3):2280-8. PubMed ID: 9499087
[TBL] [Abstract][Full Text] [Related]
30. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway.
Jeffers M; Taylor GA; Weidner KM; Omura S; Vande Woude GF
Mol Cell Biol; 1997 Feb; 17(2):799-808. PubMed ID: 9001234
[TBL] [Abstract][Full Text] [Related]
31. NF-kappa B p105 processing via the ubiquitin-proteasome pathway.
Sears C; Olesen J; Rubin D; Finley D; Maniatis T
J Biol Chem; 1998 Jan; 273(3):1409-19. PubMed ID: 9430676
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation.
Han Y; Weinman S; Boldogh I; Walker RK; Brasier AR
J Biol Chem; 1999 Jan; 274(2):787-94. PubMed ID: 9873017
[TBL] [Abstract][Full Text] [Related]
33. Ubiquitinylation and proteasome-dependent degradation of the phosphoinositide-specific phospholipase C gamma 1 in A-431 cells.
Evdonin AL; Tsupkina NV; Nikol'skii NN; Medvedeva ND
Dokl Biol Sci; 2003; 392():456-7. PubMed ID: 14650885
[No Abstract] [Full Text] [Related]
34. The ubiquitin-proteasome pathway and proteasome inhibitors.
Myung J; Kim KB; Crews CM
Med Res Rev; 2001 Jul; 21(4):245-73. PubMed ID: 11410931
[TBL] [Abstract][Full Text] [Related]
35. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7.
Yokouchi M; Kondo T; Houghton A; Bartkiewicz M; Horne WC; Zhang H; Yoshimura A; Baron R
J Biol Chem; 1999 Oct; 274(44):31707-12. PubMed ID: 10531381
[TBL] [Abstract][Full Text] [Related]
36. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
37. Signal-induced degradation of I(kappa)B(alpha): association with NF-kappaB and the PEST sequence in I(kappa)B(alpha) are not required.
Van Antwerp DJ; Verma IM
Mol Cell Biol; 1996 Nov; 16(11):6037-45. PubMed ID: 8887633
[TBL] [Abstract][Full Text] [Related]
38. Proteasome-dependent degradation of the human estrogen receptor.
Nawaz Z; Lonard DM; Dennis AP; Smith CL; O'Malley BW
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):1858-62. PubMed ID: 10051559
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells.
Zhang XM; Lin H; Chen C; Chen BD
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):127-33. PubMed ID: 10229667
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitination and proteasome mediated degradation of polo-like kinase.
Ferris DK; Maloid SC; Li CC
Biochem Biophys Res Commun; 1998 Nov; 252(2):340-4. PubMed ID: 9826531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
